Sugi Predict

Sugi Predict / Compounds / SCHEMBL4401614

SCHEMBL4401614

SCHEMBL4401614

CN1CCN(CC2CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM5 P08912 1/20 0.48
▸ ADRA2C P18825 1/20 0.48
▸ ACHE P22303 2/20 0.46
▸ NCF1 P14598 1/20 0.42
▸ CACNA2D1 P54289 1/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ CACNB1 Q02641 1/20 0.41
▸ CACNA1C Q13936 1/20 0.41
▸ KCNH2 Q12809 2/20 0.35
▸ MC4R P32245 1/20 0.35
▸ SCN1A P35498 1/20 0.35
▸ SCN4A P35499 1/20 0.35
▸ SCN7A Q01118 1/20 0.35
▸ SCN5A Q14524 1/20 0.35
▸ SCN9A Q15858 1/20 0.35
▸ SCN2A Q99250 1/20 0.35
▸ SCN3A Q9NY46 1/20 0.35
▸ SCN11A Q9UI33 1/20 0.35
▸ SCN8A Q9UQD0 1/20 0.35
▸ SCN10A Q9Y5Y9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15217800 0.93 CHRM5 (0.43) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL3436997 0.92 NCF1 (0.52) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL13981150 0.91 ACHE (0.55) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL14270469 0.91 CHRM5 (0.52) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL14409697 0.91 ACHE (0.55) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL22722602 0.91 CHRM5 (0.41) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL24319476 0.90 NCF1 (0.50) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL12772838 0.90 CHRM5 (0.62) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL2616300 0.90 CHRM5 (0.56) CHRM5ADRA2CACHENCF1CACNA2D1
SCHEMBL23173902 0.90 NCF1 (0.54) CHRM5ADRA2CACHENCF1CACNA2D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119855815-A KRAS mutant protein inhibitor, and preparation method and application thereof 甘李药业股份有限公司 2025-04-18 — — CN disclosed
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. 2024-07-04 — — US disclosed
WO-2024061333-A1 KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 甘李药业股份有限公司 2024-03-28 — — WO disclosed
EP-4076650-B1 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2024-02-28 — — EP disclosed
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 — — EP disclosed
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-08-10 — — US disclosed
US-20230219986-A1 NOVEL AMINOPYRIMIDINE EGFR INHIBITOR QILU PHARMACEUTICAL CO., LTD. (CN) 2023-07-13 — — US disclosed
US-20230219986-A1 NOVEL AMINOPYRIMIDINE EGFR INHIBITOR QILU PHARMACEUTICAL CO., LTD. (CN) 2023-07-13 — — US disclosed
EP-4129996-A1 NOVEL AMINOPYRIMIDINE EGFR INHIBITOR QILU PHARMACEUTICAL CO., LTD. (CN) 2023-02-08 — — EP disclosed
EP-4008719-A2 PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2022-06-08 — — EP disclosed
US-7342011-B2 Rifamycin analogs and uses thereof ACTIVBIOTICS, INC. (US) 2008-03-11 — — US disclosed
EP-1802307-B1 PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS GLAXO GROUP LTD (GB) 2008-02-27 — — EP disclosed
US-20080045506-A1 Pyrrolidine Derivatives as Histamine Receptors Ligands GLAXO GROUP LIMITED (GB) 2008-02-21 — — US disclosed
US-20080045506-A1 Pyrrolidine Derivatives as Histamine Receptors Ligands GLAXO GROUP LIMITED (GB) 2008-02-21 — — US disclosed
US-7271165-B2 Rifamycin analogs and uses thereof ACTIVBIOTICS, INC. (US) 2007-09-18 — — US disclosed
US-7271165-B2 Rifamycin analogs and uses thereof ACTIVBIOTICS, INC. (US) 2007-09-18 — — US disclosed
US-20070142392-A1 Uses of rifamycins ACTIVBIOTICS, INC. (US) 2007-06-21 — — US disclosed
US-20070142392-A1 Uses of rifamycins ACTIVBIOTICS, INC. (US) 2007-06-21 — — US disclosed
US-20070105849-A1 Rifamycin analogs and uses thereof ACTIVBIOTICS, INC. (US) 2007-05-10 — — US disclosed
WO-2007036532-A2 SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045506-A1 Pyrrolidine Derivatives as Histamine Receptors Ligands HRH4, HRH3, HRH2 CHRM5 185/4885ADRA2C 213/4885ACHE 354/4885
US-20070105849-A1 Rifamycin analogs and uses thereof RIF1, HDAC5, HDAC4 CHRM5 3405/4885ADRA2C 1278/4885ACHE 4631/4885
US-20070142392-A1 Uses of rifamycins TNF, TLR6, IL6 CHRM5 4603/4885ADRA2C 4462/4885ACHE 2019/4885
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN BRDT, BET1, BRD4 CHRM5 4789/4885ADRA2C 4334/4885ACHE 4827/4885
US-20230219986-A1 NOVEL AMINOPYRIMIDINE EGFR INHIBITOR EGFR, ERBB2, ERBB4 CHRM5 4082/4885ADRA2C 3745/4885ACHE 4866/4885
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS FPR2, FPR1, FPR3 CHRM5 599/4885ADRA2C 235/4885ACHE 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.